Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns
Indian J Ophthalmol
.
2021 Feb;69(2):357-358.
doi: 10.4103/ijo.IJO_39_21.
Authors
Aman Kumar
1
,
Divya Agarwal
1
,
Atul Kumar
1
Affiliation
1
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
PMID:
33463591
PMCID:
PMC7933877
DOI:
10.4103/ijo.IJO_39_21
No abstract available
Publication types
Comment
MeSH terms
Bevacizumab
Biosimilar Pharmaceuticals*
Humans
India / epidemiology
Retinal Diseases* / drug therapy
Retinal Diseases* / epidemiology
Substances
Biosimilar Pharmaceuticals
Bevacizumab